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The current autologous chimeric antigen receptor (CAR)-T cell therapy products, both commercially approved 
and in clinical development, have been instrumental in changing treatment paradigm to benefit cancer patients. 
The therapeutic success of these treatment options has, to some extent, been tempered by the challenges of 
consistently manufacturing patient-specific products and by the introduction of a  new manufacturing model 
involving scaling-out and  subsequent releasing 100-1000s of patient-specific lots.  
 
Adicetbio is building on the therapeutic success of patient-specific CAR-T cell therapies by employing gamma 
delta (gd) T cells and engineered T-cell receptor-like tumor recognition to improve the safety and efficacy of 
CAR-T cell therapies against both liquid and solid tumors. Additionally, we are optimizing the manufacture 
allogeneic CAR gd-T cells to facilitate off-the-shelf treatment of hundreds of patients per manufacturing run.   . 
This approach greatly simplifies the complexity of manufacturing associated with the autologous model through 
minimizing the variation of processing patient material and eliminating the need to support large product release 
testing infrastructure. Results will be presented outlining results of ongoing process development and 
demonstrating that, by leveraging established bioprocess platform technologies, we can efficiently engineer, 
expand, harvest, and cryopreserve up to 2x1011 CAR-T cells from a single healthy donor in a cGMP-compliant 
manner. Figure 1 outlines the CAR gd-T cell manufacturing process. This approach is scalable to both support 
the needs of internal development as well as clinical trials, achieving substantial economies of scale while 
maintaining product quality consistency.  
 
 
